Trials / Completed
CompletedNCT02935075
Optimization of Antiretroviral Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 184 (actual)
- Sponsor
- Shanghai Public Health Clinical Center · Other Government
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The combination antiretroviral therapy (cART) inhibit HIV replication effectively. However, synergy among these drugs has not been well considered. The dose of drugs used as monotherapy is the same as that used in combination therapy. Tenofovir+lamivudine+efavirenz is still the first line regimen of cART in developing countries. The side effects of these drugs are related to the concentration of drugs. Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects while not scarifying their virological efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir disoproxil fumarate | Oral daily |
| DRUG | Lamivudine | Oral daily |
| DRUG | Efavirenz | Oral daily |
Timeline
- Start date
- 2018-03-05
- Primary completion
- 2019-06-05
- Completion
- 2019-08-31
- First posted
- 2016-10-17
- Last updated
- 2020-02-18
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02935075. Inclusion in this directory is not an endorsement.